Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.


Rational Use of New and Emerging Agents for Hepatitis Delta Virus
  • CME
  • CE

Several emerging agents will soon be available for the treatment of hepatitis delta virus (HDV). Hear experts discuss rational use and combinations of new agents to treat patients with HDV.
Heiner Wedemeyer, MD
person default
Cihan Yurdaydin, MD
Physicians: maximum of 0.25 AMA PRA Category 1 Credits
Registered Nurses: 0.25 Nursing contact hours
Released: March 16, 2022 Expiration: March 15, 2023

Hepatitis delta virus (HDV) is the most severe form of viral hepatitis and warrants new treatment options for better efficacy and tolerability. In part 2 of this 2-part podcast series, hear Heiner Wedemeyer, MD, and Cihan Yurdaydin, MD, discuss their thoughts on new and emerging treatment options for HDV and rational use of these new agents. Their discussion includes:

  • Assembly inhibitors (eg, lonafarnib)
  • Entry inhibitors (eg, bulevirtide)
  • Interferon lambda
  • Nucleic acid polymers
  • Small interfering RNA (siRNA) agents

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Apply optimal treatment strategies for patients with chronic HDV infection
  • Recount key safety and efficacy data from clinical trials of investigational agents for chronic HDV

Information on this Educational Activity

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:


Heiner Wedemeyer, MD

Professor and Chairman
Department of Gastroenterology, Hepatology and Endocrinology
Hannover Medical School
Hannover, Germany

Heiner Wedemeyer, MD, has disclosed that he has received consulting fees from AbbVie, Aligos, Altimmune, Biotest, Bristol-Myers Squibb, BTG, Dicerna, Enanta, Gilead Sciences, Janssen, MSD/Merck, MYR GmbH, Roche, and Vir; has received funds for research support from AbbVie, Biotest, Gilead Sciences, MSD/Merck, and Roche; and has served as a clinical trials investigator for AbbVie, Altimmune, Bristol-Myers Squibb, Gilead Sciences, Janssen, MSD/Merck, MYR GmbH, Novartis, and Vir.
Cihan Yurdaydin, MD
Professor and Chief, Department of Gastroenterology and Hepatology
Koç University Medical School
Istanbul, Turkey
Cihan Yurdaydin, MD, has disclosed that he has received consulting fees from Gilead Sciences and fees for non-CME/CE services from AbbVie and Gilead Sciences.


Sarah Anderson, PharmD
Scientific Director
Sarah L. Anderson, PharmD, has no relevant conflicts of interest to report.
Zachary Schwartz, MSc

Scientific Director

Zachary Schwartz, MSc, ELS, has no relevant conflicts of interest to report.
Kiran D. Mir-Hudgeons, PhD

Manager, Editorial Operations

Kiran D. Mir-Hudgeons, PhD, has no relevant conflicts of interest to report.
Julie Skowronski, NP
Julie Skowronski, FNP, has no relevant conflicts of interest to report.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.


Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Target Audience

This program is intended for physicians, registered nurses, nurse practitioners, physician associates/physician assistants, and other healthcare professionals who provide care for patients with HDV infection.


The goal of this program is to improve healthcare professionals’ awareness of HDV and the importance of screening in patients with HBV, as well as their competence in treating patients with HBV/HDV coinfection.


Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation

CCO designates this enduring material for a maximum of 0.25 AMA PRA Category I Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Education

Credit Designation

The maximum number of hours awarded for this Continuing Nursing Education activity is 0.25 contact hours.

Program Medium

This program has been made available online.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 0.25 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from March 16, 2022, through March 15, 2023:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 100% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.


Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Educational grant provided by:
Gilead Sciences, Inc.

Related Content

Prof George Lau: proactive monitoring and treatment are necessary for all patients with CHB, regardless of age, from Clinical Care Options (CCO)

George Lau, MBBS (HKU), MD (HKU), FRCP (Edin, Lond), FAASLD (USA) Released: December 1, 2022

Expert summaries of AASLD, EASL, APASL guidance on monitoring and treating chronic hepatitis B and delta infections, with Maria Buti, Paul Kwo, Grace Wong

Maria Buti, MD Paul Y. Kwo, MD Grace LH Wong, MD Released: December 1, 2022

Expert summaries of AASLD, EASL, and APASL guidance on monitoring and treating chronic hepatitis B and delta viral infections, from Clinical Care Options (CCO)

Maria Buti, MD Paul Y. Kwo, MD Grace LH Wong, MD Released: December 1, 2022

Professor Graham Foster shares his approach to the management of hepatitis B in older adults, from Clinical Care Options (CCO)

Graham R. Foster, FRCP, PhD Released: November 18, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.


Cookie Settings